4934
Premier Anti-Aging Co.,Ltd.
プレミアアンチエイジング
- Industry
- Chemicals
- Market
- Growth
- Accounting standards
- Japanese GAAP
- Consolidation basis
- Consolidated
Key metrics
Revenue(million JPY)
Jul 2021
32,815
Jul 2022
33,912
Jul 2023
26,401
Jul 2024
20,359
Jul 2025
16,160
Operating profit(million JPY)
Jul 2021
4,680
Jul 2022
2,414
Jul 2023
-612
Jul 2024
139
Jul 2025
617
Operating profit margin(%)
Jul 2021
14.26
Jul 2022
7.12
Jul 2023
-2.32
Jul 2024
0.68
Jul 2025
3.82
Profit before tax(million JPY)
Jul 2021
4,653
Jul 2022
2,572
Jul 2023
-659
Jul 2024
-902
Jul 2025
588
Profit(million JPY)
Jul 2021
2,794
Jul 2022
1,424
Jul 2023
-734
Jul 2024
-1,483
Jul 2025
471
Total assets(million JPY)
Jul 2021
13,071
Jul 2022
12,300
Jul 2023
12,135
Jul 2024
11,002
Jul 2025
10,140
Cash and cash equivalents(million JPY)
Jul 2021
6,052
Jul 2022
2,963
Jul 2023
4,659
Jul 2024
4,753
Jul 2025
4,655
Cash flows from operating activities(million JPY)
Jul 2021
2,753
Jul 2022
-3,322
Jul 2023
2,423
Jul 2024
425
Jul 2025
1,472
Cash flows from investing activities(million JPY)
Jul 2021
-181
Jul 2022
-298
Jul 2023
-901
Jul 2024
-540
Jul 2025
-229
Cash flows from financing activities(million JPY)
Jul 2021
1,585
Jul 2022
502
Jul 2023
180
Jul 2024
183
Jul 2025
-1,337
Return on equity(%)
Jul 2021
66.9
Jul 2022
18.68
Jul 2023
-
Jul 2024
-
Jul 2025
7.42
Equity ratio(%)
Jul 2021
52.81
Jul 2022
67.87
Jul 2023
62.71
Jul 2024
55.67
Jul 2025
65.07
Earnings per share(JPY per share)
Jul 2021
326.87
Jul 2022
163.35
Jul 2023
-84.17
Jul 2024
-170.1
Jul 2025
54.1
Net assets per share(JPY per share)
Jul 2021
791.65
Jul 2022
957.3
Jul 2023
872.6
Jul 2024
702.33
Jul 2025
756.65
Dividend per share(-)
Jul 2021
-
Jul 2022
-
Jul 2023
-
Jul 2024
-
Jul 2025
-
Payout ratio(-)
Jul 2021
-
Jul 2022
-
Jul 2023
-
Jul 2024
-
Jul 2025
-
Disclaimer
The financial information and metrics on this page are based on publicly available filings and other public sources. We do not guarantee their accuracy, completeness, or timeliness.
The information on this page is provided for reference purposes only and does not constitute a recommendation to buy or sell any security. Investment decisions should be made at your own responsibility.